Australia sees COVID-19 突発／発生 leveling off
By Sonali Paul
MELBOURNE, Oct 4 (Reuters) - Australia's Delta 突発／発生 appears to have leveled off, with more than half the country in 延長するd lockdowns and ワクチン接種 率s starting to approach 国家の 的s, Health 大臣 Greg 追跡（する） said on Monday.
追跡（する） said 80% of Australians will have had their first COVID-19 jabs this week, while the 全体にわたる 戦う／戦い against the ウイルス has been 上げるd by the arrival in 最近の days of 15,000 付加 doses of 治療 麻薬 sotrovimab.
The Australian 政府 wants all COVID-19 制限s, 含むing travel 禁止（する）s, to be 解除するd when 80% of the 全住民 above 16 is fully vaccinated. It 推定する／予想するs that 的 will be reached in 中央の-November.
"There are important 推論する／理由s for hope," 追跡（する） told reporters in a テレビ放送するd 圧力（をかける） 会議／協議会, pointing to a 法外な 落ちる in new 事例／患者s in New South むちの跡s 明言する／公表する, home to Australia's biggest city Sydney.
"Victoria, yes, it is a big challenge ... But we are beginning to see the flattening of the curve in Victoria," he said.
New South むちの跡s on Monday 報告（する）／憶測d 623 new 事例／患者s and six deaths, 負かす／撃墜する from more than 900 事例／患者s a day a week ago.
Victoria 明言する／公表する 報告（する）／憶測d 1,377 new COVID-19 感染s, up from 1,220 on Sunday, but off a 記録，記録的な／記録する high of 1,488 on Saturday. There were four new deaths.
公式の／役人s have 非難するd a 最近の spike in Victoria's 事例／患者s on Australian 支配するs football final parties, in 違反 of strict lockdown 支配するs the previous 週末. Nearly half of the new 事例／患者s on Monday were people between the ages of 10 and 29.
The 明言する／公表する's 資本／首都 Melbourne, in the 中央 of its sixth lockdown, on Sunday reached a cumulative total of 245 days of 制限s since March last year, 追いつくing Buenos 空気／公表するs as the city under the longest lockdown, によれば 地元の マスコミ.
にもかかわらず the 現在の downtrend, 専門家s have 警告するd that 事例／患者s are likely to rise again once the country 現れるs from lockdown, replicating the experience in other countries that vaccinated earlier.
New South むちの跡s is 予定 to start 緩和 抑制（する）s from Oct. 11, the first Monday after it 推定する／予想するs 70% of its 全住民 over 16 to be fully vaccinated, up from 67% now.
Victoria hopes to reach the 70% 的, up from about 52% now, by Oct. 26.
GlaxoSmithKline and Vir 生物工学's sotrovimab has been shown to be 効果的な in 減ずるing 入院 and death の中で high-危険 COVID-19 患者s when given 早期に in the 病気.
追跡（する） said he hoped another COVID-19 麻薬, a pill 存在 実験（する）d by Merck & Co Inc, would be 利用できる in Australia in the first ４半期/4分の1 of 2022.
(報告（する）／憶測ing by Sonali Paul; Editing by Himani Sarkar and Richard Pullin)
